S
6.94
0.25 (3.74%)
| Previous Close | 6.69 |
| Open | 6.69 |
| Volume | 2,843,727 |
| Avg. Volume (3M) | 1,962,995 |
| Market Cap | 1,412,066,816 |
| Price / Book | 14.92 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.490 |
| Total Debt/Equity (MRQ) | 20.08% |
| Current Ratio (MRQ) | 14.91 |
| Operating Cash Flow (TTM) | -95.63 M |
| Levered Free Cash Flow (TTM) | -56.02 M |
| Return on Assets (TTM) | -38.97% |
| Return on Equity (TTM) | -75.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Savara, Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.0 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.38% |
| % Held by Institutions | 98.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (JMP Securities, 58.50%) | Buy |
| Median | 9.50 (36.89%) | |
| Low | 9.00 (Wells Fargo, 29.68%) | Buy |
| 9.00 (Oppenheimer, 29.68%) | Buy | |
| Average | 9.75 (40.49%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 4.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 18 Dec 2025 | 9.00 (29.68%) | Buy | 6.59 |
| Oppenheimer | 14 Nov 2025 | 9.00 (29.68%) | Buy | 4.30 |
| Citizens | 13 Nov 2025 | 10.00 (44.09%) | Buy | 4.26 |
| JMP Securities | 23 Oct 2025 | 11.00 (58.50%) | Buy | 4.12 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |